BN-82451 2HCl is a dual inhibitor of COX-1 and COX-2 and can be used to study Huntington's chorea and Parkinson's disease.

1 - 10 mg/kg oral doses of BN82451 reduced the severity of fully established AIMs in a dose-related manner in a rat model of PD. This antimotor dysfunction effect was achieved with subchronic administration of lower doses of BN82451 compared with acute single treatments.The improvement in AIMs was not due to a reduction in general locomotor activity in the dyskinetic rats.BN82451 treatment significantly reversed the overexpression of c-Fos, FosB, and Arc mRNAs, which have been associated with the dyskinetic effects of levodopa.The effect of BN82451 was not due to a reduction in general motor activity in the dyskinetic rats. [1];After subchronic administration of 5 mg/kg/day subcutaneously for 5 days, IRC concentrations in the brain of male cynomolgus monkeys (Macaca fascicularis) were higher (cortex: 20.87±6.92 μM) than in plasma (1.16±0.33 μM), with a ratio of 18.2±2.5; at 2.5, 5, and 10 mg/kg IRC-082451, IRC concentrations in the brain of male cynomolgus monkeys were higher than in plasma (1.16±0.33 μM), with a ratio of 18.2±2.5. Subcutaneous injection into Macaca fascicularis quantified L-DOPA-induced dyskinesia and showed no significant effect on spontaneous motor activity in all acute treatments tested. [3]